Deoxycoformycin in the treatment of patients with hairy cell leukemia: Results of a Spanish collaborative study of 80 patients

Cancer

Volumn 88, Issue 2, 2000, Pages 352-357

  Rafel, Montserrat ^g   Cervantes, Francisco ^g   Beltrán, José Maria ^a   Zuazu, Francisco ^b   Nieto, Luis Hernández ^c   Rayón, Consuelo ^d   Talavera, Juan García ^e   Montserrat, Emilio ^f  

^a HOSPITAL DE BASURTO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g NONE

Author keywords

Deoxycoformycin; Hairy cell leukemia; Purine analogs; Treatment

Indexed keywords

ALPHA INTERFERON; PENTOSTATIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; SPLENECTOMY; TREATMENT OUTCOME; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; PENTOSTATIN; RECURRENCE; TREATMENT OUTCOME;

EID: 0034650780     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000115)88:2<352::AID-CNCR15>3.0.CO;2-8     Document Type: Article

References (28)

1. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2436-74.
2. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988;72:1069-73.
3. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991;5(Suppl):133-8.
4. Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler D, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10:371-7.
5. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-21.
6. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-15.
7. Spiers ASD, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2-deoxycoformycin). J Clin Oncol 1984;2:1336-42.
8. Kraut EH, Bouroncle BA, Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 1986; 68:1119-22.
9. Cassileth PA, Cheuvart B, Spiers ASD, Harrington DP, Cummings FJ, Neiman RS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991;9:243-6.
10. Ribeiro P, Bouaffia F, Peaud PY, Blanc M, Salles B, Salles G, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1998;85:65-71.
11. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchinsson RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-81.
12. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 1992;79:1111-20.
13. Zaja F, Fanin R, Silvestri F, Russo D, Infanti L, Baccarani M. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-I and/or 2-chlorodeoxyadenosine. Haematologica 1997;82:468-70.
14. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Cox DR. The analysis of binary data. London: Mathew and Co., 1970:90-8.
16. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
17. Dixon WJ, Brown MB, Engelman L, Hill MA, Jennrich RI, Dixon WJ, editors. BMDP statistical software. Berkeley, CA: University of California Press, 1988;719-43.
18. Annino L, Ferrari A, Giona F, Cimino G, Crescenzi S, Cava MC, et al. Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leuk Lymphoma 1994;14(Suppl):115-9.
19. Catovsky D, Matutes E, Talavera JG, O'Connor NTJ, Johnson SAN, Emmett E, et al. Long term results with 2-deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994; 14(Suppl):109-13.
20. Golomb HM, Dodge R, Mick R, Budman D, Hutchinson R, Horning SJ, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. Leukemia 1994;8:2037-40.
21. Seymour IF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-I-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997;11:42-7.
22. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF. 2-Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann Intern Med 1988;108:733-43.
23. Urba WJ, Baseler MW, Koop WC, Steis RG, Clark JW, Smith JW, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989;73:38-46.
24. Steis RG, Urba WJ, Kopp WC, Alvord WG, Smith JW, Longo DL. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 1991;83:1678-9.
25. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2-deoxycoformycin. Blood 1994;84:4061-3.
26. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CDA). Blood 1992;79:882-7.
27. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997;15:1138-42.
28. Legrand O, Vekhoff A, Marie JP, Zittoun R, Delmer A. Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (2-CDA): identification of parameters predictive of adverse effects. Br J Haematol 1997;99:165-7.